SyMap Medical Ltd, a China-based company focused on developing device therapies for the unmet clinical needs of cardiovascular and pulmonary diseases, announced on Wednesday that it has collaborated with Pythagoras Medical, a medical device company established by Rainbow Medical, an Israel-based medical device investment group.

Under the partnership SyMap has full rights to utilise all assets of Pythagoras, including its Renal Nerve Mapping System (ConfidenHT, CE Mark Approval,) patents, trademarks and expertise. The collaboration is intended to further improve and consolidate SyMap's patent range and ensure its position in the domain of Renal Denervation.

SyMap is carrying out two pivotal trials in China, the first is the SMART Study (NCT02761811) utilising the SyMapCath I Catheter/SYMPIONEER S1 RF system for the treatment of uncontrolled hypertension, and the second trial is the BATA Study (NCT03765307) that assesses the efficiency and safety of the Elation system to treat severe asthma through bronchial radiofrequency ablations.